Theralase Technologies (Theralase Technologies) EV-to-EBITDA : -11.74 (As of May. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Theralase Technologies's enterprise value is $28.13 Mil. Theralase Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.40 Mil. Therefore, Theralase Technologies's EV-to-EBITDA for today is -11.74.

The historical rank and industry rank for Theralase Technologies's EV-to-EBITDA or its related term are showing as below:

TLTFF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.43 Med: -9.32 Max: -1.55
Current: -11.89

During the past 13 years, the highest EV-to-EBITDA of Theralase Technologies was -1.55. The lowest was -30.43. And the median was -9.32.

TLTFF's EV-to-EBITDA is ranked worse than
100% of 488 companies
in the Medical Devices & Instruments industry
Industry Median: 16.205 vs TLTFF: -11.89

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Theralase Technologies's stock price is $0.1155. Theralase Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.013. Therefore, Theralase Technologies's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Theralase Technologies EV-to-EBITDA Historical Data

The historical data trend for Theralase Technologies's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies EV-to-EBITDA Chart

Theralase Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-8.08

-5.84

-17.66

-13.92

-9.48

Theralase Technologies Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-10.58	-13.92	-12.75	-16.44	-9.48

Competitive Comparison of Theralase Technologies's EV-to-EBITDA

For the Medical Devices subindustry, Theralase Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's EV-to-EBITDA falls into.

Theralase Technologies EV-to-EBITDA Calculation

Theralase Technologies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	28.129	/	-2.397
	=	-11.74

Theralase Technologies's current Enterprise Value is $28.13 Mil.
Theralase Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.40 Mil.

Theralase Technologies (OTCPK:TLTFF) EV-to-EBITDA Explanation

Theralase Technologies's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.1155	/	-0.013
	=	At Loss

Theralase Technologies's share price for today is $0.1155.
Theralase Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.013.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Theralase Technologies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies (Theralase Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.